Xequel Bio

Focus: Xequel Bio is a pre-revenue biotech company focused on peptide therapeutics for injury healing and related indications. The company operates from Mount Pleasant, SC with a portfolio spanning wound healing, burn treatment, and ophthalmology.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Xequel Bio

AI assessmentNot Hiring

No open roles listed right now. Follow Xequel Bio to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

0/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Granexin® gel

Diabetic Foot Ulcers

Phase 1

FSR Peptide 20μM

Wound Heal

Phase 1

iNexin™

Dry Eye Disease

Help build intelligence for Xequel Bio

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage peptide platform with multiple clinical-stage programs (Phase 1–3) across high-unmet-need indications like diabetic foot ulcers and burn wounds
Lead candidate Granexin® gel has reached Phase 3 for diabetic foot ulcers, indicating de-risking and potential near-term regulatory catalysts
Opportunity to build foundational expertise in peptide drug development and commercialization from ground level at a focused biotech

Watch Out For

Zero active job postings and no disclosed employee count suggest minimal current hiring; company scale and headcount trajectory are opaque
No reported publications, funding disclosures, or recent news; lack of transparency on financial runway, investor backing, or clinical trial recruitment status raises visibility concerns
Early clinical stage (majority Phase 1–2) with zero active trials reported; long development timeline ahead before revenue inflection or exit catalysts

Xequel Bio

About Xequel Bio

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Open Jobs (0)